IgA Nephropathy

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

New study finds SGLT2 inhibitors reduce proteinuria in IgA nephropathy, with greater initial eGFR dips predicting stronger treatment responses.

Study results showed systemic corticosteroids induced greater remission rates alone than in combination with other immunosuppressive treatments but were linked to adverse events.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

The multicenter study examined the presentation and outcomes of patients with cirrhosis-related IgAN and compared clinicopathological profiles with primary IgAN.

Findings suggest the potential prognostic value of time-averaged serum uric acid for predicting disease progression in IgAN.

Proteinuria < 1 g/d is the current treatment target, but findings suggest patients with uACR between 0.3 and 1.0 g/g face a substantial risk of adverse kidney outcomes.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

Findings showed the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition may refine the histological assessment of IgAN.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

Urinary cytokines GDF-15, IL-6, and EGF significantly strengthened the predictability of IgAN prognosis and may be viable biomarker candidates for disease progression.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.

Barratt discusses results from subgroup analyses of the phase 3 PROTECT trial based on baseline proteinuria and what they add to previous findings.

Barratt discusses the potential of targeting the alternative pathway for controlling inflammation and the significance of the new APPLAUSE-IgAN data.

RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.

Results suggest low-dose corticosteroids in combination with leflunomide are more efficacious for improving urine protein excretion with better safety than full-dose corticosteroids.

Our March 2024 month in review highlights HCPLive’s top coverage of the latest news in nephrology, ranging from new CKD research and KDIGO guidelines to recent IgAN data.

Both high blood pressure and triglycerides were identified as risk factors for IgAN, although high blood pressure was deemed to have the most direct influence.